Similarly, another biallelic EIF2AK4 mutation was reported [c.1392delT(p.Arg465fs)], where the PVOD patient demonstrated compliance with PAH-targeted drugs [10]. The gene discussed is EIF2AK4; the disease is pulmonary venoocclusive disease.